Category Archives: Cell Therapy

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics (CYTX) today announced two independent investigator-sponsored and funded cell therapy clinical studies in Japan have been approved by the Ministry of Health, Labor and Welfare under the Guidelines on Clinical Research Using Human Stem Cells. One study will investigate the use of Cytoris cell therapy as a treatment for ischemic heart failure and the other as a treatment for cirrhosis of the liver. The studies will be performed by Shuichi Kaneko, M.D., Ph.D., Professor and Chairman of Departments of Gastroenterology, and Disease Control and Hemostasis, Graduate School of Medicine at Kanazawa University Hospital School of Medicine.

In each study, patients will receive an injection of Cytoris cell therapy, which consists of their own adipose-derived stem and regenerative cells (ADRCs) processed at the point-of-care using the Cytoris proprietary and automated Celution System. The ischemic heart failure study will enroll patients with low left ventricular function due to a prior heart attack and the ADRCs will be delivered through the coronary artery. In the study of patients with cirrhosis of the liver, the ADRCs will be delivered through the hepatic artery.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution system product family. http://www.cytori.com

Link:
Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan

By Erika Sauler Philippine Daily Inquirer

MANILA, Philippines This type of stem cell therapy does not claim to be the fountain of youth, but an alternative treatment to arthritis, muscle pain and tendon tear.

Two Filipino doctors who trained in the United States said in a media forum on Sunday that autologous stem cell therapy could speed up the healing of musculoskeletal and sports-related injuries, which could be an optional remedy before undergoing surgery.

Dr. Jeimylo de Castro explained that the procedure would involve taking stem cells from the patients blood, fat tissue or bone marrow and injecting them to the injured area of the same person. This type of therapy is different from the controversial embryonic stem cells which are harvested from animals or fertilized eggs.

With stem cell therapy being a current fad for anti-aging, the Department of Health has warned the public that the benefits of stem cell therapy are still under evaluation. The DOH will soon issue guidelines for the use of stem cell therapy and the licensing of facilities offering this service.

De Castro and Dr. Franklin Domingo are both fellows of the Philippine Academy of Rehabilitation Medicine. They underwent training for stem cell therapy under Dr. Joseph Purita of the Institute of Regenerative and Molecular Orthopaedics, and Dr. Sherwin Kevy of Harvards Immune Disease Institute.

If you have arthritis and you take anti-inflammatory drugs, you will not feel the pain so you will move around and further damage the cartilage. Whereas stem cells will regenerate tissues and ease the pain, making the damaged cells become young again, De Castro said.

Domingo likened the stem cells to high school students who have no career yet and could be trained to be professionals in a field where they are needed. So if the stem cells are injected into an injured knee, they will develop into tissues that hasten the recovery of the area.

According to Domingo, stem cell therapy is not for everybody and is not a quick-fix solution because it uses the bodys natural ability to heal.

Patients who have cancer and infection are not allowed to undergo stem cell therapy, and so are those under the influence of alcohol or who have taken blood-thinning medicine like Coumadin at the time of extraction.

Read more:
Stem cell therapy for muscle, sports injury alternative to surgery

SANTA ANA, Calif.--(BUSINESS WIRE)--

Irvine Scientific, a leading cell culture media/ medical device company for more than 40 years, announced their newly launched cell therapy PRIME-XV product portfolio as part of the companys commitment to accelerate basic research and clinical applications in cell therapy and regenerative medicine. Using their expertise in cell culture media development, PRIME-XV products were designed to function as part of an integrated workflow solution in culturing primary cells, where all products have been pre-validated to decrease end user qualification time. Initially, PRIME-XV products will comprise of a serum-free medium for the expansion of human mesenchymal stromal/ stem cells (MSCs), biopreservation solutions and extracellular matrix proteins. However, Irvine Scientific intends to expand this product line to offer other cell culture media and reagents, such as stem cell qualified fetal bovine serum, tumorsphere and neural progenitor cell expansion media. Examples of existing PRIME-XV products include:

PRIME-XV MatrIS F: a recombinant human matrix protein intended for the culture of human stem/ progenitor cells under serum-free conditions. PRIME-XV MatrIS F provides an alternative substrate to the PRIME-XV Human Fibronectin product, which has a wide variety of applications in primary cell spreading and attachment.

PRIME-XV MSC EXPANSION SFM: a complete, serum-free expansion medium specifically designed for the culture of primary human MSCs derived from bone marrow and adipose tissues. This medium is supplied as a convenient one 250mL bottle and is ready-to-use without the need of additional cytokine/ growth factor supplements. MSCs cultured in PRIME-XV MSC EXPANSION SFM out performed serum-containing medium as well as leading competitors in cell expansion studies without losing their multipotent characteristics or immune modulation functions.

PRIME-XV Hypothermic Biopreservation Solution: a protein-free, defined solution intended for storage and stable shipping of cells and tissue samples under hypothermic (2-8C) condition. By preserving cells above freezing temperature, it reduces cellular stress response associated from chilling and re-warming of cells and tissues, and retains high culture viabilities after recovery. Simply replace the culture medium with this animal component-free, cGMP manufactured product for short term storage. To recover from preservation, PRIME-XV Hypothermic Biopreservation Solution is removed and replaced with growth medium of choice.

As an alternative to the PRIME-XV Hypothermic Biopreservation Solution, Irvine Scientific also carries a protein-free, defined PRIME-XV Cryogenic Preservation Solution, which allows for cryopreservation of biologics at -80C to -196C.

About Irvine Scientific

Irvine Scientific, a member of JX group, is a worldwide leader in the design, manufacture and distribution of medical devices, including Cell Therapy, Industrial Cell Culture, Cytogenetic and Assisted Reproductive Technology products. We are a large scale producer of advanced quality cell culture media for the cell therapy, industrial bioprocess, medical and diagnostic markets. Our companys extensive experience in the design of culture media, compliance with ISO and FDA regulations for class II/III medical devices and industrial scale manufacturing capacity provides our customers with unique capabilities and support. Irvine Scientific delivers products worldwide to the biopharmaceutical industry, research and medical laboratory communities.

For more information:

- Visit http://www.irvinesci.com

See the original post here:
Irvine Scientific Offers Cell Therapy Products

By Philip C. Tubeza Philippine Daily Inquirer

Stem cell therapy might provide a remedy for acquired immunodeficiency syndrome (AIDS) after it was used on an HIV patient in Germany, the first person known to have been cured of the disease, a Department of Health (DOH) official said Tuesday.

Dr. Gerald Belimac, program manager of the DOH National AIDS/Sexually Transmitted Infection Prevention and Control Program, said American Timothy R. Brown, the so-called Berlin Patient who had been infected with the human immunodeficiency virus, was cured after getting stem cells in 2007 from a donor who was genetically resistant to the virus that caused AIDS.

However, he said that this procedure was very complex and was still under study.

It takes the right person, the right recipient, the right donor, for a stem cell transplantation particularly on HIV to be successful, Belimac said.

If it comes from other donors, there is really a high chance that the recipient would reject it, she added.

Brown was infected with HIV in 1995 and was later diagnosed with leukemia, or cancer of the blood.

He underwent a transplant of stem cells for the leukemia and it turned out that those stem cells had genes that were resistant to HIV, Belimac said.

Medical research has shown that almost 5 percent of Caucasians are genetically resistant to HIV, he said, but there are still no studies showing Filipinos having similar genes.

Read more here:
A first: Stem cell therapy cures HIV patient in Germany

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics (CYTX) today announced two independent investigator-sponsored and funded cell therapy clinical studies in Japan have been approved by the Ministry of Health, Labor and Welfare under the Guidelines on Clinical Research Using Human Stem Cells. One study will investigate the use of Cytoris cell therapy as a treatment for ischemic heart failure and the other as a treatment for cirrhosis of the liver. The studies will be performed by Shuichi Kaneko, M.D., Ph.D., Professor and Chairman of Departments of Gastroenterology, and Disease Control and Hemostasis, Graduate School of Medicine at Kanazawa University Hospital School of Medicine.

In each study, patients will receive an injection of Cytoris cell therapy, which consists of their own adipose-derived stem and regenerative cells (ADRCs) processed at the point-of-care using the Cytoris proprietary and automated Celution System. The ischemic heart failure study will enroll patients with low left ventricular function due to a prior heart attack and the ADRCs will be delivered through the coronary artery. In the study of patients with cirrhosis of the liver, the ADRCs will be delivered through the hepatic artery.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution system product family. http://www.cytori.com

Originally posted here:
Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan

SALT LAKE CITY, UT--(Marketwire - Oct 25, 2012) - Q Holdings, Inc., dba Q Therapeutics, Inc., an emerging biotechnology company utilizing its proprietary innovative technology to develop breakthrough cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that Deborah Eppstein, PhD, President and CEO, will be presenting at the 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum -- a premier business development and partnering meeting for regenerative medicine companies.

The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine (CIRM) to profile the industry's most exciting technologies.Thirty-five companies and organizations will be presenting over the course of two days, ranging from translational research centers to emerging-growth biotech companies, as well as established, publicly traded industry leaders.

The following are specific details regarding Q Therapeutics' presentation at the conference:

Date: October 29, 2012

Time: 10:15 AM PDT

Location: Sanford Consortium for Regenerative Medicine Building Auditorium, Second Floor Terrace 2880 Torrey Pines Scenic Drive La Jolla, California

The Investor and Partnering Forum was created in 2011 to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings.It will be held immediately prior to the Stem Cell Meeting on the Mesa's Scientific Symposium organized by the Sanford Consortium, and the combined meetings are expected to attract over 800 attendees from around the globe. The company presentations will be recorded by ARM and will be made available on ARM's website shortly after the event. To learn more or to register for the 2012 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit http://www.stemcellmeetingonthemesa.com.Registration is required.

About Q Therapeutics, Inc. Headquartered in Salt Lake City, Utah, Q Holdings, Inc., dba Q Therapeutics, Inc., is a fully reporting, non-trading company, engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system.The Company's first product, Q-Cells, is a cell-based therapeutic intended to restore or preserve normal function of neurons by providing essential support functions that occur in healthy central nervous system tissues.Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy, and stroke, as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), spinal cord injury, Parkinson's disease and Alzheimer's disease.Q Therapeutics' initial clinical target is ALS, with a first IND filing expected in 2013.For more information, visit http://www.qthera.com.

Cautionary Statement Regarding Forward Looking Information This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Q Therapeutics' technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of its intellectual property rights.Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Q Therapeutics' periodic reports, including the quarterly report on Form 10-Q for the period ended June 30, 2012.

See the original post:
Q Therapeutics CEO to Present at 2012 Stem Cell Meeting on the Mesa

MANILA, Philippines Amid the recent warning issued by the Department of Health (DOH) regarding stem cell therapy, doctors who are offering the treatment in the Philippines clarified that they are not promising a cure.

We are very careful about claiming cure. These days ang dami nagsasalita, nawala ang sakit. All of a sudden siya (stem cell therapy) na yung magic bullet ng buong mundo, like if you get stem cell, you get cured, said Dr. Michelle de Vera, deputy director of the Institute of Personalized Molecular Medicine at The Medical City.

Kapag may narinig na ganyan dapat lalo silang mag-ingat. Cure is zero evidence of disease or kung genetic yung disease dapat napalitan yung genes mo. Hindi mangyayari yun at this point," he stressed.

De Vera, an allergologist and immunologist, does stem cell therapy on her patients at The Medical City but he said he believes that the DOH is right in warning patients on stem cell therapy.

Tama naman na magbigay sila ng warning,I think what their trying to do is regulate stem cell therapy, the doctor said.

Public advisory

The DOH recently came out with a public advisory on stem cell therapies saying that there is an "observed proliferation of centers offering stem cell treatments for medical and aesthetic purpose, and although this technology holds promise, stem cell therapy is not yet part of the standard of care and is considered an investigative procedure for compassionate use."

The DOH further stated that "applications of stem cells for the treatment of malignancies, blood disorders, degenerative diseases (e.g. Alzhimer's), metaboloc diseases (eg diabetes), and immune cell therapy are still under clinical evaluation and study."

I did not say it doesn't work but it takes a while, a lot of experiments and clinical studies before it is considered a standard of care in medicine, clarified Health Secretary Enrique T. Ona.

Ona also added in his statement that "the public is strongly advised to avoid stem cell therapies which use the following as sources for stem cells: embryonic stem cells, aborted fetuses, genetically-altered and animal fresh cells." Not from animals

See the original post here:
Doctors don't promise cure with stem cell therapy

PARIS--(BUSINESS WIRE)--

The C4C consortium today announced the implementation of France's first ever dedicated technical facility for the manufacture of cell therapy products. The C4C project (coordinated by CELLforCURE, a subsidiary of the leading French biopharmaceutical company LFB Biotechnologies) brings together the skills of two biotech companies (Celogos and CleanCells) and seven public-sector organizations and university medical centers (the French Blood Agency's [Etablissement Franais du Sang, EFS] directorates in the Aquitaine-Limousin and Pyrnes-Mditerrane regions of France, Bordeaux University Medical Center [CHU de Bordeaux], Lille University Medical Center/University of Lille 2 [CHU de Lille], Nantes University Medical Center, [CHU de Nantes] and the Biological Resource Center at Lyons University Medical Center [Banque de Tissus et de Cellules des Hospices Civils de Lyon]. The first five products are currently being developed, with a view to validating the facility dedicated to the routine production of clinical trial and therapeutic batches. This facility is located on LFB's site in Les Ulis, close to Paris.

C4C is an ambitious project that has attracted 80 million euros in investment from the consortium members and 30 million euros in public-sector financial aid (provided by OSEO, France's state innovation agency). In fact, C4C was selected by OSEO as part of the "Investing in the Future" call for tenders for France's first industry-academic gateway in the field of cell therapy research, development and industrial production. The project has attracted 30 million euros in public-sector financial aid. Thanks to C4C, academic, public- and private-sector stakeholders are provided with an industrial tool for producing both their Phase 3 clinical trial batches and commercial batches.

Lastly, the C4C project corresponds to Europe's first ever modular unit for the large-scale industrial production of novel, cell-based advanced therapy medicinal products.

Cell therapy: definitions and issues

Cell therapy involves the administration of human cells to prevent, treat or alleviate an illness. In some situations, the administered cells repair and/or rebuild damaged tissue. In others, modified cells are used to provide tissue with compounds that it previously lacked. The cell therapy market is set to be worth an estimated 5.2 billion US dollars by 2015 and could double again to reach 10 billion US dollars in 2020.

The five therapeutics currently under development and their target diseases are as follows:

1. The GRAPA Program in Phase I/II development at Bordeaux University Medical Center in collaboration with Frances National Blood Service (EFS). Hematopoietic stem cells are obtained from placental blood and amplified ex vivo prior to use for the treatment of bone marrow or lymph node malignancies (leukemia, lymphoma, myeloma), aplastic anemia, congenital immunodeficiencies and congenital enzyme deficiencies.

2. The CEL-02 cell therapeutic from Celogos, in Phase II clinical development for the treatment of anal incontinence A Phase II clinical trial is currently recruiting at Rouen University Medical Center and the start of the Phase III clinical program (to include investigators across Europe) is scheduled for 2014.

3. Autologous islet of Langerhans grafts (Lille University Medical Center/University of Lille 2), in Phase I/II clinical development for the treatment of post-pancreatectomy diabetes The procedure developed by Professor Franois Pattous group in Lille is based on an intramuscular, autologous transplant of islets of Langerhans that makes it possible to obtain long-term insulin independence in the majority of patients.

Read the rest here:
The C4C consortium Announces the Implementation of France's First Ever Facility for the Industrialization of Cell ...

WASHINGTON, DC--(Marketwire - Oct 17, 2012) - The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, announced the publication today of an article on FDA communications to help companies developing cell-based therapies by clarifying the development pathway. The article, entitled "Communications with the FDA on the Development Pathway for a Cell-Based Therapy: Why, What, When, and How?" will be published in the journal Stem Cells Translational Medicine. It is co-authored by representatives from ARM, Janssen R&D, GE Healthcare and Life Technologies, with the lead author from the California Institute for Regenerative Medicine (CIRM).

"There are a number of ways cell-based therapy companies can communicate with FDA that will help them navigate the road from the bench to a regulatory submission," said Michael Werner, Executive Director of ARM. "We hope that our combined experience as co-authors, and our attempt to create a single source of guidance on the regulatory process, will help companies bring new cell-based therapies through clinical trials and the regulatory review process more quickly so they can reach patients faster," added Mr. Werner.

Lead author Ellen Feigal, MD, Senior Vice President for Research and Development at the California Institute for Regenerative Medicine (CIRM) commented, "Cell-based therapies represent a fundamentally new way to treat or cure disease, but developing a new therapy is costly, time consuming and fraught with uncertainty. Our paper takes a practical approach to clarifying the path to market."

"Communications with the FDA on the Development Pathway for a Cell-Based Therapy: Why, What, When, and How?" provides detailed information on options for communicating with the FDA at different stages; the official communications tied to each stage of development; and the most common reasons regulatory applications are delayed. The article can be accessed at: http://stemcellstm.alphamedpress.org/content/early/recent

About CIRM: CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

About ARM: The Alliance for Regenerative Medicine is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 120 members and is the leading global advocacy organization in this field. In March 2012, ARM launched a sister organization in Europe -- the Alliance for Advanced Therapies. For more information go to http://www.alliancerm.org.

View original post here:
Journal Stem Cell Translational Medicine to Publish Article on FDA Communications and the Regulatory Pathway for Cell ...

NEW YORK, Oct. 17, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that it will redeem all outstanding shares of its Series E 7% Senior Convertible Preferred Stock ("Series E Preferred Stock").

On October 10, 2012, the Company gave notice to its Series E Preferred Stockholders that it is redeeming all of the outstanding shares of Series E Preferred Stock for an aggregate redemption price of $3.4 million, $2.5 million of which was funded by money placed into escrow when the Series E Preferred stock was issued in November 2010.

"We are pleased that we have been able to redeem this $10 million investment in full over a two year period. Equal to our focus on cell therapy product development and expanding our PCT contract development and manufacturing operations, we are committed to improving our balance sheet. Through the redemption of the Series E Preferred Stock, we will remove a significant overhang and simplify NeoStem's capital structure. The redemption of the Series E Preferred Stock is another example of a step taken by us to improve Common Stockholder value," said Dr. Robin Smith, Chairman and CEO of NeoStem. "We look forward to continued execution on our near term business strategy, including the forthcoming closing of the divestiture of our Erye China pharmaceutical subsidiary."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Read the rest here:
NeoStem, Inc. Announces the Redemption of the Outstanding 7% Series E Preferred Stock